NDA submitted for abiraterone acetate for the treatment of metastatic advanced prostate cancer

Centocor Ortho Biotech has submitted a New Drug Application (NDA) to the FDA for abiraterone acetate administered with prednisone for the treatment of metastatic advanced prostate cancer in patients who have received prior chemotherapy containing a taxane.  This submission includes data from a Phase 3, randomized, double-blind, placebo-controlled clinical study (COU-AA-301), which evaluated overall survival and tolerability in patients with metastatic advanced prostate cancer treated with abiraterone acetate plus prednisone compared to treatment with placebo plus prednisone.

Abiraterone acetate is an investigational oral androgen biosynthesis inhibitor being developed for the treatment of metastatic advanced prostate cancer that has developed resistance to conventional hormonal therapies.  This is also known as castration-resistant prostate cancer (CRPC).  It is believed that abiraterone acetate inhibits a key enzyme, CYP17, needed for androgen biosynthesis in the testes, adrenals and tumor.  

For more information call (800) 457-6399 or visit www.centocororthobiotech.com